Urtė Fultinavičiūtė
Reporter
Urtė has previously worked as a Healthcare Reporter at GlobalData Media, primarily writing for Clinical Trials Arena. She mostly focused on clinical trial data management, strategy, and regulatory updates as well as clinical trial data readouts and exclusive interviews with C-level pharma and biotech executives. Urtė holds an MA in International Journalism from City, University of London.
Latest From Urtė Fultinavičiūtė
MS Pharma Bags Formycon’s Eylea Biosimilar Rights In MENA
With an already established network, Formycon’s aflibercept biosimilar licensee Klinge follows in the same footsteps by picking MS Pharma as its MENA region partner.
Majority Of US Patent Thickets Filed Post-FDA Approval, Study Finds
As different US authorities keep pointing fingers at each other over who is responsible for improper patent listings, a study looks at patent applications that are filed after an FDA approval.
AAM Applauds CMS For Biosimilar Substitution Flexibility In Medicare Part D Plans
Despite receiving mixed opinions on the Medicare Part D final rule, CMS sees support from the off-patent group AAM, which said that the new policy will have an “immediate impact” on cost reduction and increased access to biosimilars.
Celltrion Offers 85% Discount For Adalimumab Biosimilar In US
Celltrion joins a number of other adalimumab competitors with dual pricing strategies as Humira biosimilars finally gain some traction in the US market.
Lupin’s Confidence Over Mirabegron Relaunch Doesn’t Convince Analyst
While Lupin is “truly excited with the potential” ahead, the uncertainty around upcoming product launches paints a different financial picture.
ViiV Healthcare And Medicines Patent Pool Celebrate 10-Year HIV Collaboration
On the heels of a decade-long partnership with ViiV Healthcare that has helped 24 million people with HIV, the Medicines Patent Pool introduces a new version of its patent database for essential medicines and COVID-19 vaccines.